Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals (Q80148689)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Aihua Song

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Jianxun Song

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Xiaohong Tang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Michael Croft

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

1224-1232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Costimulation of CD8 T cell responses by OX40.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Inhibition of tumor rejection by γδ T cells and IL-10

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Epitope affinity for MHC class I determines helper requirement for CTL priming.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636957

7 January 2021

Identifiers

DOI

10.1002/EJI.200636957

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17429847%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference